On 15 March, Aimmune Therapeutics, Inc. (NASDAQ:AIMT) shares decreased -6.67% and was closed at $15.53. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) year to date (YTD) performance is -15.83%.
On 3 March, Aimmune Therapeutics, Inc. (NASDAQ:AIMT) announced financial results for the fourth quarter and full year 2015 and provided a corporate update. The company recently initiated a pivotal Phase 3 trial, PALISADE, of its lead product candidate, AR101 for the treatment of peanut allergy.
SINA Corporation (NASDAQ:SINA) shares decreased -0.21% in last trading session and ended the day at $46.65. SINA Gross Margin is 61.60% and its has a return on assets of 1.90%. SINA Corporation (NASDAQ:SINA) quarterly performance is 1.11%.
On 2 March, SINA Corporation (NASDAQ:SINA) announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2015. Net revenues increased 21% year over year to $256.2 million. Non-GAAP net revenues increased 22% year over year to $253.6 million.
Sanchez Energy Corporation (NYSE:SN) caters to the Basic Materials space. Its weekly performance is 13.57%. On the last day of trading company shares ended up at $5.19. Sanchez Energy Corporation (NYSE:SN) distance from 50-day simple moving average (SMA50) is 48.19%.
Sanchez Energy Corporation (NYSE:SN) announced that Gleeson Van Riet, Senior Vice President and Chief Financial Officer of the Company, plans to resign from the position of Chief Financial Officer effective March 30, 2016 for personal reasons. Effective immediately, the Company has named Garrick (“Rick”) Hill as Interim Co-Chief Financial Officer.
UMH Properties Inc. (NYSE:UMH) shares moved up 0.39% in last trading session and ended the day at $10.38. UMH Gross Margin is 47.40% and its has a return on assets of -0.80%. UMH Properties Inc. (NYSE:UMH) quarterly performance is 12.14%.
UMH Properties Inc. (NYSE:UMH) reported Normalized Funds from Operations (“Normalized FFO”) for the year ended December 31, 2015 of $14,188,000 or $0.55 per diluted share as compared to $10,778,000or $0.48 a year ago. This represents a 14.6% increase in Normalized FFO per diluted share. Normalized FFO for the quarter was$3,817,000 or $0.14 per diluted share, as compared to $3,513,000 or $0.15 per diluted share in the prior year period. Core Funds from Operations (“Core FFO”) was $14,267,000 or $0.55 per diluted share for the year ended December 31, 2015, as compared to$12,321,000 or $0.55 per diluted share in the prior year period.
Blueprint Medicines Corporation (NASDAQ:BPMC) caters to the Healthcare space. Its weekly performance is 3.15%. On the last day of trading company shares ended up at $17.03. Blueprint Medicines Corporation (NASDAQ:BPMC) distance from 50-day simple moving average (SMA50) is -5.87%.
Blueprint Medicines Corporation (NASDAQ:BPMC) said it signed a worldwide collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche to develop therapeutics targeting kinases believed to be important in cancer immunotherapy.